SAN DIEGO, Aug. 19, 2025 (GLOBE NEWSWIRE) -- iBio, Inc. (Nasdaq: IBIO), an AI-driven innovator of precision antibody therapies, today announced the pricing of an underwritten public offering (the “offering”) of (i) pre-funded warrants to purchase 71,540,000 shares of iBio’s common stock (the “pre-funded warrants”), and (ii) accompanying Series G warrants representing the right to purchase (the “Series G warrants”) (a) 35,770,000 shares of iBio’s common stock, or pre-funded warrants in lieu thereof, and (b) ...

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (date of earliest event reported): August 18, 2025 iBio, Inc. (Exact name of registrant as specified in charter) Delaware (State or other jurisdiction of incorporation) Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of registrant under any of the following provi ...

SAN DIEGO, Aug. 18, 2025 (GLOBE NEWSWIRE) -- iBio, Inc. (Nasdaq: IBIO), an AI-driven innovator of precision antibody therapies, today announced it has commenced an underwritten public offering (the “offering”) of (i) pre-funded warrants to purchase shares of iBio’s common stock, and (ii) accompanying Series G warrants each representing the right to purchase (a) a fraction of a share of iBio’s common stock, or a pre-funded warrant in lieu thereof, and (b) Series H warrants each representing the right to purc ...

HOUSTON, Aug. 18, 2025 (GLOBE NEWSWIRE) -- Impact Biomedical Inc. (IBO) is pleased to announce that the US Patent and Trademark Office has issued U.S. patent No. 12,357,584 B2 entitled “Composition and Method of Controlling Infectious Diseases with Functional Fragrances,” developed within IBO’s 3F™ technology platform. This patent relates to unique composition and method for controlling infectious diseases. It includes compositions and formulations of constituents found in plants and fragrances produced by ...

Summary of iBio (IBIO) Conference Call - June 24, 2025 Company Overview - **Company**: iBio (IBIO) - **Focus**: Development of next-generation antibody medicines targeting obesity and its cardiometabolic complications [2][28] Industry Context - **Current Treatments**: First-generation GLP-1 receptor agonists and incretin-based therapies have transformed obesity treatment but have limitations, including gastrointestinal side effects and weight regain after discontinuation [3][4][6] - **Market Need**: There is a growing demand for new therapies that can provide durable weight loss, preserve muscle mass, and have better tolerability profiles [6][28] Core Programs and Developments 1. **iBio 600**: - **Type**: Long-acting anti-myostatin inhibitor - **Current Status**: In IND-enabling studies, with GLP toxicology studies about to begin [10][12] - **Mechanism**: Targets myostatin and GDF11, aiming to increase muscle mass and reduce fat mass [13][15] - **Preclinical Results**: In nonhuman primates, a single dose led to an 8% increase in muscle mass and a 12-15% reduction in fat mass [15] - **Projected Half-Life**: 74 to 130 days in humans, allowing for potential biannual dosing [14] 2. **iBio 610**: - **Type**: First-in-class Actin E antibody - **Current Status**: Development candidate selected, testing in nonhuman primates expected to yield data by Q3 2025 [11][19] - **Mechanism**: Promotes fat-specific weight loss without affecting muscle [19][21] - **Preclinical Results**: In obese rodents, led to a 9% reduction in total body weight, with a 26% reduction in fat mass [21] 3. **Amylin Receptor Program**: - **Current Status**: Advanced from early to late discovery, in vivo testing of multiple candidate molecules [23][24] - **Mechanism**: Targets amylin receptors to promote satiety and slow gastric emptying, potentially addressing obesity and cardiometabolic diseases [24][26] - **Unique Approach**: Utilizes AI-driven antibody discovery to create selective agonists for amylin receptor subtypes, avoiding calcitonin receptor activation [26][27] Competitive Advantages - **Integrated AI Platform**: iBio's discovery platform allows for rapid development of antibodies with high specificity and manufacturability [7][29] - **Focus on Developability**: The design process incorporates manufacturability and stability from the outset, ensuring that developed antibodies are ready for clinical use [8][29] - **Strategic Pipeline**: The company has a clear strategy to complement existing therapies and address unmet needs in obesity treatment [9][28] Market Positioning and Future Outlook - **Regulatory Goals**: iBio 600 aims for IND filing in Q1 2026 and patient dosing in Q2 2026 [12][13] - **Potential for Combination Therapies**: iBio's programs are designed to work alongside existing treatments, enhancing efficacy and addressing muscle preservation during weight loss [16][18][22] - **Long-Term Vision**: iBio is positioned to lead in the next wave of obesity therapeutics, focusing on genetically validated targets and innovative treatment strategies [29] Key Takeaways - iBio is addressing significant gaps in current obesity treatments with innovative antibody therapies - The company is leveraging advanced technology and a strategic approach to develop differentiated products - There is a strong emphasis on preclinical data supporting the efficacy and safety of their lead programs, with promising results in animal models [15][21][22]

Breakthrough Antibodies for Obesity and Cardiometabolic Diseases Investor Call June 24, 2025 Forward looking statements Certain statements in this presentation constitute "forward -looking statements" within the meaning of the Private Securities Litigation Reform Act of 1995 , as amended . Words such as "may," "might," "will," "should," "believe," "expect," "anticipate," "estimate," "continue," "predict," "forecast," "project," "plan," "intend" or similar expressions, or statements regarding intent, belief, ...

Core Insights - iBio, Inc. announced preclinical data showing that an engineered amylin receptor agonist antibody reduced acute food intake in a mouse model of obesity by 60%, comparable to a leading amylin peptide agonist which achieved a 67% reduction [1] - The findings support the potential of antibody-based agonists to meet the increasing demand for safer, longer-acting treatments for obesity and cardiometabolic diseases [1][3] - The collaboration between iBio and AstralBio has resulted in multiple novel engineered antibody agonists targeting the amylin receptor, a promising therapeutic target for obesity [2] Company Developments - The engineered antibody's selective activation of the amylin receptor may match or exceed the efficacy of dual agonism seen with DACRA, while improving tolerability [3] - iBio's proprietary Drug Discovery Platform and advanced AI capabilities enable the discovery of innovative antibodies with exceptional selectivity and potency, targeting specific amylin receptor subtypes [3] - The company aims to develop next-generation therapies to address the limitations of current obesity treatments, leveraging its advanced technology [3] Market Context - Other amylin analogs in clinical development have shown weight loss results of up to 22.7% when combined with semaglutide and 11.8% as monotherapy, indicating a competitive landscape for obesity treatments [4] - iBio's approach may enhance weight-loss efficacy compared to GLP-1 receptor agonists and provide options for patients who are intolerant or unresponsive to existing GLP-1-based therapies [4]

Core Insights - iBio, Inc. is set to announce a third target in its collaboration with AstralBio, focusing on advancements in obesity and cardiometabolic disease treatments [1][2] - The company aims to pioneer next-generation antibody medicines that are targeted, longer-lasting, and potentially better tolerated, with a strategic overview of its obesity treatment strategy [2][4] Company Overview - iBio is a biotech company utilizing AI and advanced computational biology to develop biopharmaceuticals for various diseases, including cardiometabolic diseases, obesity, and cancer [4] - The company combines proprietary 3D modeling with innovative drug discovery platforms to create a pipeline of breakthrough antibody treatments addressing significant unmet medical needs [4] Upcoming Events - A conference call is scheduled for June 24, 2025, at 8:30 a.m. ET to discuss the latest advancements and the new target in the AstralBio collaboration [1][3]

Activin E antibody demonstrates significant decrease in fat in obese mice by reducing visceral fat depots, which are strongly linked to increased risk of cardiovascular and metabolic diseases, resulting in a 26% reduction in fat mass with no loss in muscleStrong synergistic effect on fat mass (77% reduction) was observed when the Activin E antibody was combined with a GLP-1 receptor agonist, resulting in total weight loss of 35.3%, 7.5% greater than GLP-1 alone SAN DIEGO, May 05, 2025 (GLOBE NEWSWIRE) -- iB ...

[PART I. FINANCIAL INFORMATION](index=3&type=section&id=PART%20I.%20FINANCIAL%20INFORMATION) [Financial Statements](index=3&type=section&id=Item%201.%20Financial%20Statements) iBio, Inc.'s March 31, 2025, financial statements reflect significant losses, negative cash flows, and a 'Going Concern' warning [Condensed Consolidated Balance Sheets](index=3&type=section&id=Condensed%20Consolidated%20Balance%20Sheets) Total assets decreased to **$19.1 million** by March 31, 2025, from **$28.7 million** at June 30, 2024, reflecting reduced cash and equity Condensed Consolidated Balance Sheet Highlights (in thousands) | Account | March 31, 2025 (Unaudited) | June 30, 2024 | | :--- | :--- | :--- | | **Assets** | | | | Cash and cash equivalents | $4,959 | $14,210 | | Total Current Assets | $6,060 | $15,672 | | Total Assets | $19,103 | $28,734 | | **Liabilities & Equity** | | | | Total Current Liabilities | $5,397 | $3,840 | | Total Liabilities | $7,722 | $7,410 | | Total Stockholders' Equity | $11,381 | $21,324 | [Condensed Consolidated Statements of Operations](index=4&type=section&id=Condensed%20Consolidated%20Statements%20of%20Operations) Net loss from continuing operations increased to **$4.9 million** for Q3 2025 and **$13.2 million** for the nine months, driven by higher R&D Statement of Operations Summary (in thousands, except per share data) | Metric | Q3 2025 | Q3 2024 | Nine Months 2025 | Nine Months 2024 | | :--- | :--- | :--- | :--- | :--- | | Revenue | $0 | $0 | $200 | $50 | | Research and development | $1,906 | $904 | $5,088 | $4,045 | | General and administrative | $2,973 | $2,722 | $8,516 | $9,230 | | Operating loss | $(4,879) | $(3,626) | $(13,404) | $(13,225) | | Net loss from continuing operations | $(4,861) | $(2,635) | $(13,214) | $(12,197) | | Loss per share (continuing ops) | $(0.49) | $(0.71) | $(1.44) | $(5.43) | [Condensed Consolidated Statements of Stockholders' Equity](index=5&type=section&id=Condensed%20Consolidated%20Statements%20of%20Stockholders%27%20Equity) Stockholders' equity decreased from **$21.3 million** to **$11.4 million** due to a **$13.2 million** net loss, partially offset by capital raises - The accumulated deficit increased from **$(313.8) million** to **$(327.1) million** during the nine months ended March 31, 2025, due to ongoing net losses[13](index=13&type=chunk) - The company issued common stock and received proceeds from stock option exercises, which increased additional paid-in capital from **$335.2 million** to **$338.4 million** over the nine-month period[13](index=13&type=chunk) [Condensed Consolidated Statements of Cash Flows](index=6&type=section&id=Condensed%20Consolidated%20Statements%20of%20Cash%20Flows) Net cash used in operating activities was **$10.7 million** for the nine months ended March 31, 2025, resulting in a **$9.2 million** overall decrease in cash Cash Flow Summary (Nine Months Ended March 31, in thousands) | Activity | 2025 | 2024 | | :--- | :--- | :--- | | Net cash used in operating activities | $(10,689) | $(13,700) | | Net cash provided by investing activities | $697 | $1,050 | | Net cash provided by financing activities | $749 | $11,502 | | **Net decrease in cash** | **$(9,243)** | **$(1,148)** | [Notes to the Condensed Consolidated Financial Statements](index=8&type=section&id=Notes%20to%20the%20Condensed%20Consolidated%20Financial%20Statements) Notes detail the company's AI-enabled biotech transformation, 'Going Concern' warning, and significant financing activities - The company is a preclinical biotechnology company using AI and Machine Learning for developing antibodies, focusing on obesity, cardiometabolic diseases, and immune-oncology[24](index=24&type=chunk)[31](index=31&type=chunk) - Management has concluded there is substantial doubt about the Company's ability to continue as a going concern due to a history of significant losses, negative cash flows, and limited cash resources[41](index=41&type=chunk) - On December 31, 2024, the company entered an exclusive license agreement with AstralBio for a myostatin antibody (IBIO-600), paying the **$750,000** upfront fee by issuing **246,087** shares of common stock[106](index=106&type=chunk)[107](index=107&type=chunk) - Subsequent to the quarter end, on April 29, 2025, the company raised approximately **$6.2 million** in gross proceeds through a warrant inducement agreement, exercising **5.6 million** existing warrants at a reduced price and issuing new warrants[254](index=254&type=chunk) [Management's Discussion and Analysis of Financial Condition and Results of Operations](index=62&type=section&id=Item%202.%20Management%27s%20Discussion%20and%20Analysis%20of%20Financial%20Condition%20and%20Results%20of%20Operations) MD&A discusses the company's strategic shift to AI-driven antibody discovery, reiterates 'going concern' doubt, and details capital-raising efforts and operating expenses - The company's strategy is to leverage its AI platform for in-house programs, strategic collaborations, and technology licensing to create value[263](index=263&type=chunk)[266](index=266&type=chunk) - The company's pipeline is focused on two main areas: Obesity/Cardiometabolic Diseases (IBIO-600, Activin A, Activin E) and Immuno-Oncology (IBIO-101, TROP-2xCD3, MUC16xCD3, etc.)[290](index=290&type=chunk)[304](index=304&type=chunk) - A 'Going Concern' issue is highlighted, with cash as of May 1, 2025 (approx. **$10.5 million**) sufficient only through the end of Q1 fiscal 2026 without further capital[331](index=331&type=chunk)[338](index=338&type=chunk) Comparison of Operating Expenses (Three Months Ended March 31) | Expense (in millions) | 2025 | 2024 | Change | | :--- | :--- | :--- | :--- | | Research & Development | $1.9 | $0.9 | +$1.0 | | General & Administrative | $3.0 | $2.7 | +$0.3 | Comparison of Operating Expenses (Nine Months Ended March 31) | Expense (in millions) | 2025 | 2024 | Change | | :--- | :--- | :--- | :--- | | Research & Development | $5.1 | $4.0 | +$1.1 | | General & Administrative | $8.5 | $9.2 | -$0.7 | [Quantitative and Qualitative Disclosures About Market Risk](index=84&type=section&id=Item%203.%20Quantitative%20and%20Qualitative%20Disclosures%20About%20Market%20Risk) As a smaller reporting company, iBio, Inc. is not required to provide market risk disclosures - The company is a smaller reporting company and is not required to provide the information required by Item 3[368](index=368&type=chunk) [Controls and Procedures](index=84&type=section&id=Item%204.%20Controls%20and%20Procedures) Management concluded disclosure controls and procedures were effective as of March 31, 2025, with no material changes to internal control over financial reporting - The Principal Executive Officer and Principal Financial Officer concluded that the company's disclosure controls and procedures were effective as of March 31, 2025[370](index=370&type=chunk) - No changes in internal control over financial reporting occurred during the quarter ended March 31, 2025, that have materially affected, or are reasonably likely to materially affect, internal controls[371](index=371&type=chunk) [PART II. OTHER INFORMATION](index=84&type=section&id=PART%20II.%20OTHER%20INFORMATION) [Legal Proceedings](index=84&type=section&id=Item%201.%20Legal%20Proceedings) The company is not currently subject to any material legal proceedings, though ordinary course claims may arise - iBio is not currently subject to any material legal proceedings[372](index=372&type=chunk) [Risk Factors](index=85&type=section&id=Item%201A.Risk%20Factors) Significant risks include 'going concern' doubt, dependence on capital raises, potential stockholder dilution, and Nasdaq delisting risk - There is substantial doubt about the company's ability to operate as a going concern beyond the first quarter of fiscal year 2026 without raising additional capital[378](index=378&type=chunk)[379](index=379&type=chunk) - The company has a history of significant losses, with an accumulated deficit of **$327.1 million** as of March 31, 2025, and expects to incur further losses[383](index=383&type=chunk) - Future capital raises and the exercise of outstanding warrants will cause substantial dilution to existing stockholders[390](index=390&type=chunk) - Failure to comply with Nasdaq's continued listing standards could result in the delisting of the company's common stock[393](index=393&type=chunk) [Unregistered Sales of Equity Securities and Use of Proceeds](index=90&type=section&id=Item%202.%20Unregistered%20Sales%20of%20Equity%20Securities%20and%20Use%20of%20Proceeds) During Q3 FY2025, the company issued unregistered securities, including stock options to a vendor and shares to AstralBio as part of a license agreement - Issued an option to a professional service vendor to purchase **20,000** shares of Common Stock at an exercise price of **$1.83** per share[395](index=395&type=chunk) - Issued **246,087** shares of Common Stock to AstralBio on January 28, 2025, pursuant to the Myostatin License Agreement[396](index=396&type=chunk) [Defaults Upon Senior Securities](index=90&type=section&id=Item%203.%20Defaults%20Upon%20Senior%20Securities) This section is not applicable to the company [Mine Safety Disclosures](index=90&type=section&id=Item%204.%20Mine%20Safety%20Disclosures) This section is not applicable to the company [Other Information](index=90&type=section&id=Item%205.%20Other%20Information) This section details a significant post-period financing event on April 29, 2025, involving a warrant inducement agreement that generated **$6.2 million** in gross proceeds - On April 29, 2025, the company entered into an Inducement Agreement to encourage the exercise of existing warrants[401](index=401&type=chunk) - The agreement resulted in the cash exercise of warrants for **5,626,685** shares at a reduced price of **$0.86** per share, generating gross proceeds of approximately **$6.2 million**[401](index=401&type=chunk) - In consideration, the company issued new 'Inducement Warrants' to purchase up to **11,253,370** shares at an exercise price of **$0.86** per share[401](index=401&type=chunk)[402](index=402&type=chunk) [Exhibits](index=93&type=section&id=Item%206.%20Exhibits) This section lists exhibits filed with the quarterly report, including corporate governance documents, material agreements, and CEO/CFO certifications